Dr. Lindor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
13400 E Shea Blvd
Scottsdale, AZ 85259Phone+1 602-496-0789
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1983 - 1986
Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1979 - 1982- Mayo Clinic College of MedicineClass of 1979
Certifications & Licensure
MN State Medical License 1983 - 2025
AZ State Medical License 1990 - 2021
NC State Medical License 1979 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Fellow (AGAF) American Gastroenterological Association, 2007
- Fellow (FACG) American College of Gastroenterology
Clinical Trials
- Study of Combivir for Patients With Primary Biliary Cirrhosis Start of enrollment: 2004 Jan 01
- Effects of Alanine in Patients With Nonalcoholic Steatohepatitis Start of enrollment: 2004 Feb 01
- Betaine in Patients With Nonalcoholic Steatohepatitis Start of enrollment: 2003 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsPrimary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?David E J Jones, Ulrich Beuers, Alan Bonder, Marco Carbone, Emma Culver
Hepatology. 2024-11-01 - Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis.Surain B Roberts, Woo Jin Choi, Lawrence Worobetz, Catherine Vincent, Jennifer A Flemming
JHEP Reports. 2024-10-01 - 6 citationsOptimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival.C Fiorella Murillo Perez, Stephanie Ioannou, Iman Hassanally, Palak J Trivedi, Christophe Corpechot
Liver International. 2023-07-01
Press Mentions
Immunic, Inc. Announces Positive Top-Line Data from Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing CholangitisFebruary 18th, 2021
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Proof-of-Concept Clinical Trial of IMU-838 for the Treatment of Patients with Primary Sclerosing CholangitisFebruary 11th, 2020
Mayo Clinic & ASU Investigator-Initiated Study Focusing on Investigational Product for Primary Sclerosing CholangitisAugust 14th, 2019- Join now to see all
Grant Support
- Multicentered Randomized Trial Of High-Dose Urso In PSCNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2011
- Multicentered Randomized Trail Of High-Dose Urso In PSCNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2006
- Multicentered Randomized Trail Of High-Dose Urso In PSCNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2003
- Multicentered Randomized Trial Of High-Dose Urso In PSCNational Institute Of Diabetes And Digestive And Kidney Diseases2001
- Pilot Study Of Pirfenidone In PBC And PSCNational Institute Of Diabetes And Digestive And Kidney Diseases1998–1999
- Pilot Study Of Budesonide For Patients With PSC And PBCNational Institute Of Diabetes And Digestive And Kidney Diseases1997–1998
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
